Oxford BioDynamics Plc (OXBOF)
USD 0.02
(-86.0%)
USD 0.02
(-86.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 10.43 Million GBP | -51.82% |
| 2022 | 8.71 Million GBP | 25.33% |
| 2021 | 6.95 Million GBP | 45.35% |
| 2020 | 4.78 Million GBP | 14.97% |
| 2019 | 4.16 Million GBP | 34.47% |
| 2018 | 3.09 Million GBP | -5.9% |
| 2017 | 3.28 Million GBP | 33.92% |
| 2016 | 2.45 Million GBP | 48.76% |
| 2015 | 1.65 Million GBP | 70.73% |
| 2014 | 967 Thousand GBP | -13.58% |
| 2013 | 1.11 Million GBP | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 3.06 Million GBP | 24.41% |
| 2024 Q1 | 2.46 Million GBP | 1.84% |
| 2023 Q2 | 1.75 Million GBP | -27.96% |
| 2023 Q1 | 2.43 Million GBP | 56.3% |
| 2023 Q4 | 2.41 Million GBP | -27.55% |
| 2023 Q3 | 3.33 Million GBP | 90.61% |
| 2023 FY | 4.2 Million GBP | -51.82% |
| 2022 Q3 | 2.11 Million GBP | -43.53% |
| 2022 FY | 8.71 Million GBP | 25.33% |
| 2022 Q1 | 1.63 Million GBP | -50.17% |
| 2022 Q2 | 3.74 Million GBP | 129.65% |
| 2022 Q4 | 1.55 Million GBP | -26.55% |
| 2021 Q4 | 3.27 Million GBP | 56.67% |
| 2021 Q2 | 3.49 Million GBP | 88.45% |
| 2021 Q1 | 1.85 Million GBP | -29.75% |
| 2021 FY | 6.95 Million GBP | 45.35% |
| 2021 Q3 | 2.09 Million GBP | -40.1% |
| 2020 FY | 4.78 Million GBP | 14.97% |
| 2020 Q2 | 2.3 Million GBP | 81.15% |
| 2020 Q3 | 1.47 Million GBP | -35.86% |
| 2020 Q1 | 1.27 Million GBP | -42.63% |
| 2020 Q4 | 2.63 Million GBP | 78.3% |
| 2019 FY | 4.16 Million GBP | 34.47% |
| 2019 Q1 | 1.13 Million GBP | 24.22% |
| 2019 Q4 | 2.21 Million GBP | 99.73% |
| 2019 Q2 | 1.13 Million GBP | 0.0% |
| 2019 Q3 | 1.11 Million GBP | -1.99% |
| 2018 FY | 3.09 Million GBP | -5.9% |
| 2018 Q1 | 935 Thousand GBP | -11.67% |
| 2018 Q2 | 935 Thousand GBP | 0.0% |
| 2018 Q3 | 912.49 Thousand GBP | -2.41% |
| 2018 Q4 | 912.49 Thousand GBP | 0.0% |
| 2017 Q3 | 1.05 Million GBP | -33.53% |
| 2017 FY | 3.28 Million GBP | 33.92% |
| 2017 Q4 | 1.05 Million GBP | 0.0% |
| 2017 Q2 | 1.59 Million GBP | 0.0% |
| 2017 Q1 | 1.59 Million GBP | 80.76% |
| 2016 Q1 | 737 Thousand GBP | -4.04% |
| 2016 Q2 | 737 Thousand GBP | 0.0% |
| 2016 Q4 | 881 Thousand GBP | 0.0% |
| 2016 FY | 2.45 Million GBP | 48.76% |
| 2016 Q3 | 881 Thousand GBP | 19.54% |
| 2015 Q4 | 768 Thousand GBP | 0.0% |
| 2015 Q3 | 768 Thousand GBP | 167.6% |
| 2015 FY | 1.65 Million GBP | 70.73% |
| 2015 Q1 | 287 Thousand GBP | 0.0% |
| 2015 Q2 | 287 Thousand GBP | 0.0% |
| 2014 FY | 967 Thousand GBP | -13.58% |
| 2013 FY | 1.11 Million GBP | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Bioxytran, Inc. | 3.82 Million USD | -173.131% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 87.977% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -3886.612% |
| SQZ Biotechnologies Company | 85.61 Million USD | 87.813% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | -257.79% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 64.694% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 71.994% |
| Propanc Biopharma, Inc. | 1.5 Million USD | -594.72% |
| Marizyme, Inc. | 19.23 Million USD | 45.769% |
| Genus plc | 147.7 Million USD | 92.936% |
| Pharming Group N.V. | 225.49 Million USD | 95.373% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | -409.297% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -677.76% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | -25.123% |
| ContraFect Corporation | 56.88 Million USD | 81.659% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -605.595% |
| IMV Inc. | 37.7 Million USD | 72.33% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | -273.931% |
| ONE Bio Corp. | 6.44 Million USD | -61.921% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 87.86% |
| Mesoblast Limited | 5.9 Million USD | -76.788% |
| MultiCell Technologies, Inc. | 567.42 USD | -1838749.529% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 57.783% |
| Genscript Biotech Corporation | 825.34 Million USD | 98.736% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -2578.365% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | -297.104% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | -112.163% |
| Biomind Labs Inc. | 994.18 Thousand USD | -949.506% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | -492.949% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | -55.314% |
| Skye Bioscience, Inc. | 13.54 Million USD | 22.982% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | -459.653% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | -18.849% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 41836.0% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | -136.67% |
| Arch Therapeutics, Inc. | 5.04 Million USD | -106.94% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 34.829% |
| Accustem Sciences Inc. | 3.74 Million USD | -178.506% |
| EV Biologics, Inc. | 531.96 Thousand USD | -1861.418% |
| Q BioMed Inc. | 3.43 Million USD | -203.612% |
| GB Sciences, Inc. | 1.42 Million USD | -634.525% |
| Alpha Cognition Inc. | 9.7 Million USD | -7.505% |
| CSL Limited | 3.44 Billion USD | 99.697% |
| Agentix Corp. | 1.37 Million USD | -660.631% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 89.496% |
| Enzolytics Inc. | 2.17 Million USD | -378.732% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 12.71 Million USD | 17.92% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | -185.808% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 1.83 Million USD | -468.581% |
| argenx SE | 1.53 Billion USD | 99.32% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 81.835% |
| HST Global, Inc. | 140.9 Thousand USD | -7304.884% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -899.425% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -827.541% |
| Halberd Corporation | 74.84 Thousand USD | -13841.37% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | -333.858% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | -206.434% |
| Zenith Capital Corp. | 8.94 Million USD | -16.672% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | -560.649% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | -324.955% |
| AVAX Technologies, Inc. | 7.31 Million USD | -42.731% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -5983.646% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | -443.181% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -59793.232% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 2.46 Million USD | -322.984% |
| Helix BioMedix, Inc. | 1.97 Million USD | -429.098% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 3.985% |
| Kadimastem Ltd | 2.41 Million USD | -332.926% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 54.585% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -5649.235% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | -681.321% |
| LadRx Corporation | 3.81 Million USD | -173.73% |
| Cell Source, Inc. | 4.32 Million USD | -141.229% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -2411.318% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1029.82% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -1029.82% |
| Affymax, Inc. | 39.38 Million USD | 73.508% |
| Mobile Lads Corp. | 554.54 Thousand USD | -1781.539% |
| Itoco Inc. | 919.14 Thousand USD | -1035.188% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | -146.177% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -832.44% |
| International Stem Cell Corporation | 5.27 Million USD | -97.951% |
| CytoDyn Inc. | 18.05 Million USD | 42.22% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -41355.759% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -4641.046% |
| Qrons Inc. | 643.67 Thousand USD | -1520.999% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -634.896% |
| SYBLEU INC | 160.87 Thousand USD | -6385.741% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | -367.918% |
| Rebus Holdings, Inc. | 664 Thousand USD | -1471.386% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | -474.458% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -19720.676% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -51190.37% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 71.229% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | -544.87% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -1317.981% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | -235.391% |
| Neutra Corp. | 243.82 Thousand USD | -4179.369% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 40.23% |
| PureTech Health plc | 144.59 Million USD | 92.784% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 49.077% |
| IXICO plc | 4.7 Million USD | -121.67% |
| IntelGenx Technologies Corp. | 8.79 Million USD | -18.609% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 91.139% |
| CSL Limited | 3.89 Billion USD | 99.732% |
| Cellectis S.A. | 97.32 Million USD | 89.279% |